Blog
RSS FeedPosted by Michael Wonder on 06 Jul 2025
Garadacimab for the prevention of recurrent attacks of hereditary angioedema in patients 12 years of age and older
2 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 05 Jul 2025
Quebec implements public reimbursement of Pluvicto - a defining milestone for radioligand therapy in Canada
3 July 2025 - Pluvicto now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA ...
Posted by Michael Wonder on 05 Jul 2025
Teprotumumab for the treatment of patients with thyroid eye disease
2 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 04 Jul 2025
Public Summary Documents - March 2025 PBAC meeting
4 July 2025 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the March 2025 ...
Posted by Michael Wonder on 03 Jul 2025
Release of provisional recommendations for expert advisory committees
1 July 2025 - We’re improving our processes, so that people can understand the outcome of expert advice to PHARMAC earlier. ...
Posted by Michael Wonder on 03 Jul 2025
Top level push for taxpayer funding of weight loss drugs gathers pace
3 July 2025 - Pharma giants are sweating on the results of a federal government request for guidance on adding weight ...
Posted by Michael Wonder on 03 Jul 2025
Big pharma calls out Australia’s ‘freeloading’ on US medicine
3 July 2025 - American pharmaceutical manufacturers have ramped up pressure on Donald Trump to take action against Australia over its ...
Posted by Michael Wonder on 02 Jul 2025
Calls for 'missing piece' menopause drug to be added to the PBS
2 July 2025 - A key treatment which could help around one million middle-aged Australian women remains unaffordable to many ...
Posted by Michael Wonder on 02 Jul 2025
Life-saving breast cancer drug now cheaper thanks to expansion of the PBS
1 July 2025 - A potentially life-saving treatment for early-stage breast cancer will become much more affordable for hundreds of ...
Posted by Michael Wonder on 02 Jul 2025
Adagrasib for adults with previously treated, advanced, KRAS G12C mutation positive non-small-cell lung cancer
2 July 2025 - NICE is unable to make a recommendation on the use of adagrasib (Krazati) for the second-line treatment ...
Posted by Michael Wonder on 01 Jul 2025
New Zealand Pharmaceutical Schedule - 1 July 2025
1 July 2025 - The July 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 01 Jul 2025
Schedule of Pharmaceutical Benefits - 1 July 2025
1 July 2025 - The July 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 29 Jun 2025
Pegzilarginase for the treatment of patients 2 years of age and older with arginase-1 deficiency
26 June 2025 - NICE has published additional draft guidance consultation on the use of pegzilarginase in the NHS in ...
Posted by Michael Wonder on 24 Jun 2025
Australians with cystic fibrosis benefit from life changing expanded listing
24 June 2025 - More Australians living with cystic fibrosis will have affordable access to a life changing treatment option ...
Posted by Michael Wonder on 23 Jun 2025
‘Barriers lifted’: cystic fibrosis treatment reaches final waiting patients
23 June 2025 - Ex-Wallabies player Nathan Charles has lived with cystic fibrosis for decades. ...